Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength (Descending) SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
70121-1222-01 70121-1222 Docetaxel Docetaxel 80.0 mg/4mL Chemotherapy Antimitotic Agent Taxane Intravenous Jan. 19, 2018 In Use
47335-0895-40 47335-0895 Docetaxel Docetaxel 80.0 mg/4mL Chemotherapy Antimitotic Agent Taxane Intravenous Nov. 26, 2020 In Use
72485-0215-04 72485-0215 Docetaxel Docetaxel 80.0 mg/4mL Chemotherapy Antimitotic Agent Taxane Intravenous Jan. 15, 2020 In Use
43598-0259-40 43598-0259 Docetaxel Docetaxel 80.0 mg/4mL Chemotherapy Antimitotic Agent Taxane Intravenous Nov. 10, 2014 In Use
00075-8004-04 00075-8004 Docetaxel Taxotere 80.0 mg/4mL Chemotherapy Antimitotic Agent Taxane Intravenous Aug. 2, 2010 April 30, 2021 No Longer Used
00703-5730-01 00703-5730 Docetaxel Docetaxel 80.0 mg/4mL Chemotherapy Antimitotic Agent Taxane Intravenous Dec. 31, 2015 Nov. 30, 2018 No Longer Used
16714-0500-01 16714-0500 Docetaxel Docetaxel 80.0 mg/4mL Chemotherapy Antimitotic Agent Taxane Intravenous Jan. 1, 2016 Nov. 30, 2018 No Longer Used
00955-1021-04 00955-1021 Docetaxel Docetaxel 80.0 mg/4mL Chemotherapy Antimitotic Agent Taxane Intravenous Oct. 21, 2010 In Use
00003-0855-22 00003-0855 Dasatinib Sprycel 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Oct. 28, 2010 In Use
00781-2322-46 00781-2322 Aprepitant Aprepitant 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral Dec. 27, 2016 In Use
00781-2322-68 00781-2322 Aprepitant Aprepitant 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral Dec. 27, 2016 In Use
00002-2980-26 00002-2980 Selpercatinib RETEVMO 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral May 8, 2020 In Use
00002-2980-60 00002-2980 Selpercatinib RETEVMO 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral May 8, 2020 In Use
00469-0725-60 00469-0725 enzalutamide Xtandi 80.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral Aug. 4, 2020 In Use
00310-1350-30 00310-1350 Osimertinib Tagrisso 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov. 13, 2015 In Use
00310-1350-95 00310-1350 Osimertinib Tagrisso 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral March 15, 2019 In Use
13668-0592-84 13668-0592 APREPITANT APREPITANT 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral Oct. 21, 2020 In Use
13668-0592-86 13668-0592 APREPITANT APREPITANT 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral Oct. 21, 2020 In Use
54868-5231-01 54868-5231 Aprepitant Emend 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral June 29, 2005 In Use
54868-5231-02 54868-5231 Aprepitant Emend 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral June 29, 2005 In Use
54868-5231-03 54868-5231 Aprepitant Emend 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral June 29, 2005 In Use
00006-0461-01 00006-0461 Aprepitant Emend 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral March 26, 2003 In Use
00006-0461-02 00006-0461 Aprepitant Emend 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral March 26, 2003 In Use
00006-0461-06 00006-0461 Aprepitant Emend 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral March 26, 2003 April 30, 2020 In Use
00006-0461-12 00006-0461 Aprepitant Emend 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral March 26, 2003 In Use

Found 10,000 results in 2 milliseconds — Export these results